DM21-C is a peptide-linked maytansinoid system used in the investigational ADAM9-directed IMGC936 construct. Its attached component and released metabolites should be identified separately.
The IMGC936 preclinical report describes a DM21-C maytansinoid system with a cleavable tripeptide, site-specific conjugation and loading of approximately two. Earlier peer-reviewed chemical work studied peptide-cleavable self-immolative maytansinoids with different side chains and stereochemistry. That design family should not be collapsed into DM1 or DM4.
A 2019 conference abstract reports DM51 as a major released catabolite of its DM21-C conjugates by LC-MS. That conference observation does not make DM51 an alias for the attached DM21-C system or identify every compound number in related papers. The IMGC936 phase 1/2 registry is completed and has posted results; no patient-benefit estimate is inferred here from the preclinical report or registry state.
Showing the technology this term belongs to: Antibody-drug conjugate (ADC).
DM21-C linker-payload system · Which chemical it is · from an experiment
DM21-C is used with a cleavable tripeptide and site-specific conjugation in IMGC936.
Where: IMGC936 preclinical design. How: Chemical design, cell assays, xenografts and nonhuman primate studies.
The preclinical report does not establish patient benefit or a universal property of all maytansinoids.
Checked 2026-11-09.
DM51 · How it is released · from a conference abstract
The abstract identifies DM51 as a major released catabolite of its DM21-C conjugates.
Where: Conjugates described in AACR 2019 abstract 538. This is conference evidence, not a patient outcome report. How: LC-MS identification of a major catabolite in the reported conjugate experiments.
DM51 is not an alias for the attached DM21-C system. The Elicit DOI spelling resolved to a different canonical DOI in Crossref; that discrepancy is retained in the source receipt.
Checked 2026-11-09.
DM21-C maytansinoid system · Drug molecules per antibody · from an experiment
The preclinical report describes loading of approximately two.
Product: IMGC936
Where: The named IMGC936 product or preparation described by the source. How: Design and characterisation of the preclinical site-specific construct.
This report does not assign a loading constant to every construct carrying this cargo or infer a patient dose.
Checked 2026-11-09.
Shares Bystander effect (ADC), Tubulin inhibitor payloads, Drug efflux pumps (ABC transporters), Next-generation antibody-conjugate payloads.
Shares Tubulin inhibitor payloads, Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Tubulin inhibitor payloads, Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Tubulin inhibitor payloads, Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Tubulin inhibitor payloads, Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Bystander effect (ADC), Tubulin inhibitor payloads, Drug efflux pumps (ABC transporters), Payload (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/